Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effect of Immune X on Common Cold Incidence in Healthy Adults (CELFI)

21 augustus 2026 bijgewerkt door: Givaudan France Naturals

The Effect of Immune X on the Incidence of the Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections. The main questions it aims to answer are:

  • Does Immune X reduce the proportion of participants who experience at least one clinically confirmed common cold event during the study period?
  • Does Immune X affect the number, duration, and severity of common cold events?

Researchers will compare Immune X to a placebo (a look-alike capsule containing inactive ingredients) to see if Immune X helps prevent common cold events.

Participants will:

  • Take Immune X or placebo daily for 16 weeks during the winter season.
  • Attend study visits at the beginning and end of the study and complete questionnaires and symptom assessments throughout the study.
  • Record cold symptoms, medications, and other study information using a smartphone application.
  • Provide blood and stool samples during the study.

Studie Overzicht

Toestand

Nog niet aan het werven

Studietype

Ingrijpend

Inschrijving (Geschat)

160

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Men and women aged 18 to 65 years.
  • History of at least two upper respiratory tract infections during the previous winter season.
  • Body mass index between 18 and 30 kg/m².
  • Generally healthy, as determined by the investigator.
  • Women of childbearing potential must have a negative pregnancy test and agree to use an effective method of contraception during the study.
  • Covered by French health insurance.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • Current or recent upper respiratory tract infection or COVID-19 infection within 2 weeks before enrollment.
  • Acute gastrointestinal infection, including gastroenteritis, within 2 weeks before enrollment.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before enrollment.
  • Use of systemic antibiotics within 3 months before enrollment.
  • Receipt of any vaccination within 6 weeks before enrollment.
  • Surgery requiring general anesthesia within 1 month before enrollment.
  • History of chronic respiratory disease, including asthma or chronic obstructive pulmonary disease.
  • Food allergy or chronic/recurrent allergic upper airway conditions requiring regular medical treatment, including moderate to severe allergic rhinitis, hay fever, or chronic rhinosinusitis.
  • Acute lower respiratory tract infection within 6 months before enrollment or ongoing long COVID.
  • Immunodeficiency (including HIV infection) or autoimmune disease, except stable hypothyroidism.
  • Severe or uncontrolled chronic disease, including cancer, significant liver, pancreatic, biliary, or renal disease, inflammatory bowel disease, or cardiovascular disease requiring intensive medical management.
  • Untreated or inadequately controlled diabetes.
  • History or current diagnosis of periodontitis.
  • Current chemotherapy, immunosuppressive therapy, or chronic treatment with corticosteroids or opioids.
  • Specific diets or major dietary changes within 3 months before enrollment, including high-protein, vegan, low-calorie, or low-FODMAP diets, or participation in a weight-loss program.
  • Current use of dietary supplements that may affect immune or gut microbiota parameters, or discontinuation of such supplements less than 6 weeks before enrollment.
  • Current smoking or e-cigarette use, or smoking cessation within 6 months before enrollment.
  • Current drug or alcohol abuse, or a history of abuse within the previous 12 months.
  • Regular consumption of more than 2 alcoholic drinks per day and unwillingness to maintain stable drinking habits during the study.
  • Unwillingness to refrain from using over-the-counter cold remedies, nasal washes or sprays, antihistamines, corticosteroids, or NSAIDs during the study.
  • More than 8 hours per week of vigorous physical activity or planned major changes in physical activity during the study.
  • Any condition or circumstance that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with study participation or interpretation of study results.
  • Current participation in another clinical trial or being in an exclusion period from a previous clinical trial.
  • Pregnant or breastfeeding.
  • Persons deprived of liberty, under legal protection, or unable to provide informed consent.
  • Individuals who have reached the regulatory compensation limit for participation in clinical research.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Immune X
80 participants who meet the eligibility criteria will be randomized to the experimental arm and will receive Immune X for 16 weeks.
500 mg Immune X daily as capsules for 16 weeks.
Placebo-vergelijker: Placebo
80 participants who meet the eligibility criteria will be randomized to the placebo arm and will receive placebo for 16 weeks.
Matching placebo capsules daily for 16 weeks.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Participants With at Least One Clinically Confirmed Cold Event
Tijdsspanne: Week 2 to Week 16
Proportion of participants with at least one clinically confirmed cold event.
Week 2 to Week 16

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Clinically Confirmed Cold Events
Tijdsspanne: Week 2 to Week 16
Mean number of clinically confirmed cold events per participant.
Week 2 to Week 16
Duration of Clinically Confirmed Cold Events
Tijdsspanne: Week 2 to Week 16
Duration of clinically confirmed cold events measured in days.
Week 2 to Week 16
Upper Respiratory Symptoms of Clinically Confirmed Cold Events
Tijdsspanne: Week 2 to Week 16
Wisconsin Upper Respiratory Symptom Survey (WURSS-24): Zero is equivalent to no symptoms and 7 indicates severe.
Week 2 to Week 16
Cold Symptoms of Clinically Confirmed Cold Events
Tijdsspanne: Week 2 to Week 16
Jackson Cold Scale: 0 is equivalent to absent symptoms and 3 indicates severe symptoms
Week 2 to Week 16
Illness-Specific Quality of Life During Cold Events
Tijdsspanne: Week 2 to Week 16
Wisconsin Upper Respiratory Symptom Survey (WURSS-24) quality-of-life score: Zero is equivalent to no interference and 7 indicates severe interference.
Week 2 to Week 16
Time to First Clinically Confirmed Cold Event
Tijdsspanne: Week 2 to Week 16
Number of days from Day 15 after randomization to the first clinically confirmed cold event.
Week 2 to Week 16
Fatigue
Tijdsspanne: Baseline, Weeks 4, 8, 12, and 16
Chalder Fatigue Questionnaire (CFQ-11) total score: 0 is equivalent to less/better than usual and 33 indicates much more/much worse than usual.
Baseline, Weeks 4, 8, 12, and 16
Use of Rescue Medication During Cold Events
Tijdsspanne: Week 2 to Week 16
Number of doses and duration of rescue medication use during cold events.
Week 2 to Week 16
Number of Cold Events (Clinically Confirmed and Unconfirmed)
Tijdsspanne: Week 2 to Week 16
Mean number of clinically confirmed and unconfirmed cold events per participant.
Week 2 to Week 16
Adverse Events
Tijdsspanne: Baseline through Week 16
Number of participants with adverse events.
Baseline through Week 16

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Carole Perrin, MD, Cen Experimental

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 september 2026

Primaire voltooiing (Geschat)

30 april 2027

Studie voltooiing (Geschat)

30 april 2027

Studieregistratiedata

Eerst ingediend

17 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

21 augustus 2026

Eerst geplaatst (Werkelijk)

26 augustus 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

26 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

21 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • C1775
  • 2026-A00903-48 (Andere identificatie: ID-RCB)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren